Would a CYP2B6 test help HIV patients being treated with efavirenz?

Pharmacogenomics

Volumn 14, Issue 9, 2013, Pages 999-1001

  Sukasem, Chonlaphat ^a   Sungkanuparph, Somnuek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

CYP2B6; Efavirenz; HIV; Pharmacogenetics; Polymorphism; Toxicity

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ;

AMNESIA; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; EXCITABILITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NEUROTOXICITY; PHARMACOGENETICS; PSYCHOPATHY; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CENTRAL NERVOUS SYSTEM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84880469141     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.69     Document Type: Review

References (15)

1. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308, 387-402 (2012).
2. Sungkanuparph S, Techasathit W, Utaipiboon C et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed. 4, 515-528 (2010).
3. Shubber Z, Calmy A, Andrieux-Meyer I et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: A systematic review and meta-analysis. AIDS doi:10.1097/ QAD.0b013e32835f1db0 (2013) (Epub ahead of print).
4. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71-75 (2001).
5. Gounden V, van Niekerk C, Snyman T et al. Presence of the CYP2B6 516G>T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res. Ther. 7, 32 (2010).
6. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 15, 1803-1818 (2011).
7. Maimbo M, Kiyotani K, Mushiroda T et al. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur. J. Clin. Pharmacol. 68, 267-271 (2012).
8. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: An adult AIDS Clinical Trials Group study. AIDS 18, 2391-2400 (2004).
9. Sukasem C, Cressey TR, Prapaithong P et al. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br. J. Clin. Pharmacol. 74, 1005-1012 (2012).
10. Sukasem C, Chamnanphol M, Koomdee N et al. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections. Drug Metab. Pharmacokinet. doi:http://dx.doi.org/10.2133/dmpk.DMPK- 12-RG-120 (2013) (Epub ahead of print).
11. Manosuthi W, Sukasem C, Lueangniyomkul A et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz levels in HIV/tuberculosis co-infected patients. Antimicrob. Agents Chemother. 57, 1019-1024 (2013).
12. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61, 914-918 (2008).
13. Fabbiani M, Bracciale L, Ragazzoni E et al. Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. Infection 39, 563-569 (2011).
14. StÅhle L, Moberg L, Svensson JO et al. Efavirenz plasma concentrations in HIV-infected patients: Inter- and intraindividual variability and clinical effects. Ther. Drug Monit. 26, 267-270 (2004).
15. Gatanaga H, Hayashida T, Tsuchiya K et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 .*6 and .*26. Clin. Infect. Dis. 45, 1230-1237 (2007